Bausch + Lomb Will Acquire XIIDRA from Novartis
Bausch + Lomb Corporation has entered into a definitive agreement with Novartis to acquire XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop approved to treat the…
Bausch + Lomb Corporation has entered into a definitive agreement with Novartis to acquire XIIDRA (lifitegrast ophthalmic solution) 5%, a non-steroid eye drop approved to treat the…